Helicos Announces Order for a Helicos Genetic Analysis System from a Leading U.S. Cancer Center for Cancer Stem Cell Research

2008-08-05 06:00:00

Helicos Announces Order for a Helicos Genetic Analysis System from a Leading U.S. Cancer Center for Cancer Stem Cell Research

CAMBRIDGE, Mass.–(EMWPresswire)–Helicos BioSciences Corporation

(NASDAQ:HLCS) today announced that a leading U.S. cancer research center

has placed an order for a Helicos Genetic

Analysis System for use in a cutting-edge research program involving

cancer stem cell biology. The Helicos Genetic Analysis System was chosen

because of its unique capability of true direct DNA measurement which

provides the most unbiased view of DNA and RNA critical for stem cell

research.

About Helicos BioSciences

Helicos BioSciences is a life science company focused on innovative

genetic analysis technologies for the research, drug discovery, and

diagnostic markets. Helicos’ proprietary True Single Molecule Sequencing

(tSMS) technology allows direct measurement

of billions of strands of DNA, enabling scientists to perform

experiments and ask questions never before possible. Helicos is a

recipient of the $1,000 genome grant and is committed to providing

scientists the tools to unlock the era of genomic medicine. The

company’s corporate headquarters are located at One Kendall Square,

Building 700, Cambridge, MA 02139, and its telephone number is (617)

264-1800. For more information, please visit www.helicosbio.com.

Certain statements made in this press release that are not based on

historical information are forward-looking statements which are made

pursuant to the safe harbor provisions of the Private Securities

Litigation Reform Act of 1995. This press release contains

express or implied forward-looking statements relating to, among other

things, Helicos’ expectations concerning the fulfillment of the order

discussed in this press release and management’s plans, objectives and

strategies. These statements are neither promises nor guarantees,

but are subject to a variety of risks and uncertainties, many of which

are beyond Helicos’ control, which could cause actual results to differ

materially from those contemplated in these forward-looking statements.

In particular, the risks and uncertainties include, among other things,

our ability to successfully complete the manufacturing process and

commercialize the Helicos Genetic Analysis System; competition; changing

technology and customer requirements; our ability to operate in an

emerging market; market acceptance of our technology; our ability to

retain our personnel and hire additional skilled personnel; our ability

to manage our rapid growth and our ability to obtain capital when

desired on favorable terms. Existing and prospective investors

are cautioned not to place undue reliance on these forward-looking

statements, which speak only as of the date hereof. Helicos

undertakes no obligation to update or revise the information contained

in this press release, whether as a result of new information, future

events or circumstances or otherwise. For additional disclosure

regarding these and other risks faced by Helicos, see the disclosure

contained in Helicos’ public filings with the Securities and Exchange

Commission.

Helicos BioSciences Corporation
Justine Alonzo, 617-264-1822
Investor

Relations
InvestorRelations@helicosbio.com
or
Racepoint

Group
Media Contact
Alicia Rampulla, PhD, 781-487-4680
Account

Supervisor
arampulla@racepointgroup.com

free cash grants, free grant money, free money, cash grants, scholarships, business grants, foundation grants, government grants, debt grants, consolidation, college tuition, financial aid, medical grants, personal grants, medical bills, unsecured loans, no interest loans, financing, loans, capital, non profit organizations

Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89

Get Unlimited Organic Website Traffic to your Website
TheNFG.com now offers Organic Lead Generation & Traffic Solutions